PITTSBURGH, Oct. 11, 2019 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the addition of Steven Dowdy, Ph.D., to its scientific advisory board (SAB). Dr. Dowdy joins preeminent scientists George Church, Ph.D., and Samuel Broder, M.D., on the NeuBase SAB.
“Dr. Dowdy’s considerable expertise in RNA therapeutics perfectly complements the expertise of our current SAB as well as the direction of our company, and we are fortunate to have him as an advisor as we advance our PATrOL™-enabled therapies,” said Dietrich Stephan, Ph.D., chief executive officer of NeuBase. “Attracting these renowned scientists to our team, all leading experts in their respective fields, demonstrates the immense promise and breadth of the PATrOL platform. We are hard at work turning that promise into reality for patients who are currently suffering from devastating genetic diseases.”Dr. Dowdy added, “NeuBase’s PATrOL™ platform is a powerful tool for addressing diseases characterized by genetic mutations, including cancer. PATrOL™-enabled drugs can access targets that no other antisense therapies are able to access, such as double-stranded genomic DNA and miRNA, as well as mRNA secondary structures. In addition, the inventors of the PATrOL™ platform have published on the ability to have single-base discriminatory power which opens up a world of potential selectivity for disease-causing mutations. I look forward to helping advance a new generation of therapeutics and bringing the promise of the PATrOL platform into reality.”Dr. Dowdy is a cancer biologist, specializing in the development of RNA therapeutics and in understanding cell cycle controls. He is a professor of cellular and molecular medicine at the University of California, San Diego, School of Medicine, where his research focuses on the delivery of therapeutics into cells, including the development of targeting and endosomal escape technologies. Dr. Dowdy is also a member of the Board of Directors of the Oligonucleotide Therapeutics Society.About NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL™ technology, NeuBase aims to first tackle rare, genetic neurological disorders.Use of Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the Company’s goals and plans. These forward-looking statements are distinguished by use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” or “intend,” the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company’s plans to develop and commercialize its product candidates; the timing of initiation of the Company’s planned clinical trials; the timing of the availability of data from the Company’s clinical trials; the timing of any planned investigational new drug application or new drug application; the Company’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company’s product candidates; the Company’s commercialization, marketing and manufacturing capabilities and strategy; the Company’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 535-7746NeuBase Media Contacts:
Travis Kruse, Ph.D.
Russo Partners, LLC
travis.kruse@russopartnersllc.com
OP: (212) 845-4272
Bay Street News